$LNTH
Lantheus Holdings, Inc. Stock $lnth

$lnth Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022003657 Filed on February 24, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$129.6M	$425.2M	$94.15M
YoY Change	37.61%	25.28%	5.38%
Cost Of Revenue	$71.65M	$237.5M	$53.20M
YoY Change	34.69%	18.37%	18.8%
Gross Profit	$57.91M	$187.7M	$40.95M
YoY Change	41.41%	35.26%	-8.11%
Gross Profit Margin	44.7%	44.14%	43.49%
Selling, General & Admin	$81.95M	$218.8M	$25.14M
YoY Change	225.99%	98.62%	-9.21%
% of Gross Profit	141.52%	116.58%	61.39%
Research & Development	$11.29M	$44.97M	$12.64M
YoY Change	-10.66%	37.14%	185.33%
% of Gross Profit	19.5%	23.96%	30.87%
Depreciation & Amortization	$12.20M	$42.29M	$8.390M
YoY Change	45.41%	71.28%	137.01%
% of Gross Profit	21.07%	22.53%	20.49%
Operating Expenses	$93.25M	$263.8M	$37.78M
YoY Change	146.81%	84.52%	17.58%
Operating Profit	-$35.34M	-$60.83M	$3.170M
YoY Change	-1214.76%	1348.9%	-74.51%
Interest Expense	-$1.640M	$7.752M	-$2.870M
YoY Change	-42.86%	-18.22%	37.98%
% of Operating Profit			-90.54%
Other Income/Expense, Net	-$4.029M	-$7.350M	$550.0K
YoY Change	-832.55%	-434.39%	-106.91%
Pretax Income	-$41.01M	-$75.04M	-$2.840M
YoY Change	1343.91%	553.7%	-218.33%
Income Tax	-$792.0K	-$3.759M	$570.0K
% Of Pretax Income
Net Earnings	-$40.22M	-$71.28M	-$3.410M
YoY Change	1079.33%	429.05%	-132.63%
Net Earnings / Revenue	-31.04%	-16.76%	-3.62%
Basic Earnings Per Share		-$1.06
Diluted Earnings Per Share	-$593.9K	-$1.06	-$50.93K
COMMON SHARES
Basic Shares Outstanding	67.69M shares	67.49M shares	66.87M shares
Diluted Shares Outstanding		67.49M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.51M	$98.51M	$79.60M
YoY Change	23.75%	23.75%	-14.32%
Cash & Equivalents	$98.51M	$98.51M	$79.61M
Short-Term Investments
Other Short-Term Assets	$12.82M	$12.82M	$9.625M
YoY Change	33.17%	-13.97%	32.16%
Inventory	$35.13M	$35.13M	$35.74M
Prepaid Expenses	$10.11M		$9.175M
Receivables	$89.34M	$89.34M	$54.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$235.8M	$235.8M	$184.2M
YoY Change	27.99%	28.01%	6.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$116.8M	$125.6M	$120.2M
YoY Change	-2.83%	-9.41%	3.15%
Goodwill	$61.19M		$58.63M
YoY Change	4.36%		273.12%
Intangibles	$348.5M		$376.0M
YoY Change	-7.31%		5025.57%
Long-Term Investments
YoY Change
Other Assets	$38.76M	$92.73M	$60.63M
YoY Change	-36.08%	-17.42%	180.36%
Total Long-Term Assets	$628.0M	$628.0M	$685.6M
YoY Change	-8.4%	-8.4%	194.24%
TOTAL ASSETS
Total Short-Term Assets	$235.8M	$235.8M	$184.2M
Total Long-Term Assets	$628.0M	$628.0M	$685.6M
Total Assets	$863.8M	$863.8M	$869.8M
YoY Change	-0.69%	-0.69%	114.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.79M	$20.79M	$16.28M
YoY Change	27.65%	27.53%	-12.49%
Accrued Expenses	$58.07M	$54.31M	$41.70M
YoY Change	39.25%	47.59%	11.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.64M	$11.64M	$20.70M
YoY Change	-43.76%	-43.76%	104.09%
Total Short-Term Liabilities	$90.50M	$90.50M	$80.50M
YoY Change	12.41%	12.42%	21.77%
LONG-TERM LIABILITIES
Long-Term Debt	$163.1M	$163.1M	$197.7M
YoY Change	-17.49%	-17.49%	7.49%
Other Long-Term Liabilities	$124.9M	$145.7M	$63.39M
YoY Change	97.02%	88.28%	123.24%
Total Long-Term Liabilities	$288.0M	$308.8M	$261.1M
YoY Change	10.31%	12.27%	22.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$90.50M	$90.50M	$80.50M
Total Long-Term Liabilities	$288.0M	$308.8M	$261.1M
Total Liabilities	$399.3M	$399.3M	$355.6M
YoY Change	12.3%	12.3%	22.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$221.2M		-$149.9M
YoY Change	47.54%		9.87%
Common Stock	$686.1M		$666.2M
YoY Change	2.99%		164.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$464.4M	$464.4M	$514.2M
YoY Change
Total Liabilities & Shareholders Equity	$863.8M	$863.8M	$869.8M
YoY Change	-0.69%	-0.69%	114.28%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$40.22M	-$71.28M	-$3.410M
YoY Change	1079.33%	429.05%	-132.63%
Depreciation, Depletion And Amortization	$12.20M	$42.29M	$8.390M
YoY Change	45.41%	71.28%	137.01%
Cash From Operating Activities	$13.89M	$53.92M	$570.0K
YoY Change	2336.67%	228.84%	-97.46%
INVESTING ACTIVITIES
Capital Expenditures	-$4.544M	-$12.14M	-$3.780M
YoY Change	20.21%	-2.65%	-20.25%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$15.82M	$0.00
YoY Change		109.3%
Cash From Investing Activities	-$4.544M	$3.683M	-$3.780M
YoY Change	20.21%	-174.98%	-20.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$767.0K
YoY Change		12.3%
Debt Paid & Issued, Net		$43.35M
YoY Change		179.83%
Cash From Financing Activities	-2.100M	-$39.33M	-4.370M
YoY Change	-51.95%	79.92%	54.96%
NET CHANGE
Cash From Operating Activities	13.89M	$53.92M	570.0K
Cash From Investing Activities	-4.544M	$3.683M	-3.780M
Cash From Financing Activities	-2.100M	-$39.33M	-4.370M
Net Change In Cash	7.245M	$17.96M	-7.580M
YoY Change	-195.58%	-275.62%	-151.01%
FREE CASH FLOW
Cash From Operating Activities	$13.89M	$53.92M	$570.0K
Capital Expenditures	-$4.544M	-$12.14M	-$3.780M
Free Cash Flow	$18.43M	$66.06M	$4.350M
YoY Change	323.75%	128.84%	-83.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001521036
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#LongTermDebtNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2020Q4	us-gaap	Goodwill Goodwill	58632000	USD
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36569
CY2021	dei	Entity Registrant Name EntityRegistrantName	LANTHEUS HOLDINGS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2318913
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	331 Treble Cove Road
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	North Billerica
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01862
CY2021	dei	City Area Code CityAreaCode	978
CY2021	dei	Local Phone Number LocalPhoneNumber	671-8001
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021	dei	Trading Symbol TradingSymbol	LNTH
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	163121000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197699000	USD
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1849900000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67753459	shares
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98508000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79612000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	89336000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54002000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	35129000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	35744000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12818000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9625000	USD
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5242000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	235791000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	184225000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	116772000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	120171000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	348510000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	376012000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	61189000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	62764000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16284000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	58068000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	70147000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38758000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60634000	USD
CY2021Q4	us-gaap	Assets Assets	863784000	USD
CY2020Q4	us-gaap	Assets Assets	869821000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11642000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20701000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	20787000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	41726000	USD
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1793000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	90497000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	80504000	USD
CY2021Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	20833000	USD
CY2020Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	14020000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124894000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	63393000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	399345000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	355616000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-485000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67739000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67739000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66875000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66875000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	677000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	669000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	685472000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	665530000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221225000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149946000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2048000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	464439000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	514205000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	863784000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	869821000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	425208000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	339410000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	347337000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	237513000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	200649000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	172526000	USD
CY2021	us-gaap	Gross Profit GrossProfit	187695000	USD
CY2020	us-gaap	Gross Profit GrossProfit	138761000	USD
CY2019	us-gaap	Gross Profit GrossProfit	174811000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	68422000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	40901000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	41888000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	150395000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69270000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61244000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44966000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32788000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20018000	USD
CY2021	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	263783000	USD
CY2020	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	142959000	USD
CY2019	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	123150000	USD
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	15263000	USD
CY2020	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-60825000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-4198000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	51661000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021	us-gaap	Interest Expense InterestExpense	7752000	USD
CY2020	us-gaap	Interest Expense InterestExpense	9479000	USD
CY2019	us-gaap	Interest Expense InterestExpense	13617000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	889000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3196000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7350000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2198000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6221000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75038000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11479000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28627000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3759000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1994000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3040000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71279000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13473000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67486000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54134000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38988000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67486000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54134000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40113000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71279000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13473000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-124000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	330000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	148000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	1687000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	-1418000	USD
CY2020	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	760000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1563000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1088000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	148000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69716000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14561000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31815000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	71002000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	148000	USD
CY2019	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	1746000	USD
CY2019	lnth	Vesting Of Restricted Stock Awards Value Net VestingOfRestrictedStockAwardsValueNet	0	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2454000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12492000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	114601000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13473000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1088000	USD
CY2020	lnth	Vesting Of Restricted Stock Awards Value Net VestingOfRestrictedStockAwardsValueNet	0	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2129000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3776000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	394334000	USD
CY2020	lnth	Adjustments To Additional Paid In Capital Fair Value Of Replacement Options Related To Business Acquisition AdjustmentsToAdditionalPaidInCapitalFairValueOfReplacementOptionsRelatedToBusinessAcquisition	7125000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14075000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	514205000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71279000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1563000	USD
CY2021	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	6062000	USD
CY2021	lnth	Vesting Of Restricted Stock Awards Value Net VestingOfRestrictedStockAwardsValueNet	0	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2046000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15934000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	464439000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71279000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13473000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	42288000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	24689000	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	13379000	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	9729000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	9935000	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	lnth	Asset Retirement Obligation Acceleration Expense AssetRetirementObligationAccelerationExpense	5259000	USD
CY2020	lnth	Asset Retirement Obligation Acceleration Expense AssetRetirementObligationAccelerationExpense	0	USD
CY2019	lnth	Asset Retirement Obligation Acceleration Expense AssetRetirementObligationAccelerationExpense	0	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	676000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	119000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	978000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	72400000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2000000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	889000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3196000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	4057000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2365000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1851000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15934000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	14075000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	12492000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	15263000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2250000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-286000	USD
CY2021	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	4437000	USD
CY2020	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	-1334000	USD
CY2019	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	9725000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-7121000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2218000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-10635000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-7912000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2828000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-13156000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2512000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1525000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-282000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33102000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7462000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-156000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3549000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8459000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1994000	USD
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	73000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1941000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2411000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5425000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3233000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4224000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	16145000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4161000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6077000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	53916000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	16396000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	80384000	USD
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	12140000	USD
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	12474000	USD
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	22061000	USD
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	15823000	USD
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	USD
CY2020	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	10000000	USD
CY2019	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	USD
CY2021	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	USD
CY2020	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	17562000	USD
CY2019	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3683000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4912000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22061000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	767000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	683000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	573000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3777000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	199461000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	43348000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15491000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	275376000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1224000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2258000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5295000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1173000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2046000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2129000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2454000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-39332000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-21861000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-78881000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-310000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17957000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10225000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20482000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82694000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92919000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113401000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100651000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82694000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92919000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98508000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79612000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92919000	USD
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	941000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2227000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4175000	USD
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2143000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1262000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2141000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100651000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82694000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92919000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6284000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9368000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	12253000	USD
CY2021	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	315000	USD
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	331000	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	2000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	215000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	340000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	274000	USD
CY2021	lnth	Consideration Transferred In Acquisition ConsiderationTransferredInAcquisition	0	USD
CY2020	lnth	Consideration Transferred In Acquisition ConsiderationTransferredInAcquisition	419009000	USD
CY2019	lnth	Consideration Transferred In Acquisition ConsiderationTransferredInAcquisition	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”). See “Progenics Acquisition”.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops, manufactures and commercializes innovative diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. The Company believes its diagnostic products result in improved diagnostic information that enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payors and throughout the healthcare system.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commercial products are used by cardiologists, internal medicine physicians, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists and urologists working in a variety of clinical settings. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company produces and markets its products throughout the U.S., selling primarily to clinics, group practices, hospitals, integrated delivery networks and radiopharmacies. The Company sells its products outside the U.S. through a combination of direct distribution in Canada and third party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s microbubble ultrasound enhancing agent, DEFINITY, are generated in the U.S. and Canada through a DEFINITY direct sales team. Sales of the Company’s prostate cancer diagnostic imaging agent, PYLARIFY (as defined below), are generated in the U.S. through a PYLARIFY direct sales team and a sales team at some of our positron emission tomography (“PET”) manufacturing facilities (“PMF”) partners. In the U.S., the Company’s other nuclear imaging products, including TechneLite, Xenon, NEUROLITE and Cardiolite, are primarily sold to commercial radiopharmacies, the majority of which are controlled by or associated with GE Healthcare, Cardinal, UPPI, Jubilant Radiopharma and PharmaLogic. A small portion of the Company’s nuclear imaging product sales in the U.S. are generated through the Company’s direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. AZEDRA sales are generated in the U.S. through an AZEDRA direct sales team. We have licensed RELISTOR to Bausch, and the Company collects quarterly royalties based on those sales.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains its own direct sales force in Canada for certain of its products. In Europe, Australia, Asia-Pacific, Central America and South America, the Company generally relies on third party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s headquarters are located in North Billerica, MA, with additional offices in Somerset, NJ, Montreal, Canada and Lund, Sweden.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progenics Acquisition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”).</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent has begun. Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company currently estimates could be approximately $100.0 million). The Company will issue the aforementioned cash payments related to the CVRs during the first quarter of 2023 and the first quarter of 2024 respectively. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the Effective Time, which exchange ratio was 0.31, the same as the Exchange Ratio. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 8, “Business Combinations”, for further details on the acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYLARIFY Approval and Commercial Launch</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, the Company announced that the FDA had approved PYLARIFY, a fluorine-18- (“F 18”) labeled PET imaging agent targeting prostate-specific membrane antigen (“PSMA”). PYLARIFY is a radioactive diagnostic agent indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and with suspected recurrence based on elevated serum prostate-specific antigen (“PSA”) levels. PYLARIFY is a product in the Company’s radiopharmaceutical oncology product category.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced its commercial launch of PYLARIFY in the U.S. in June 2021. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercial launch in June 2021, PYLARIFY was immediately available in select parts of the U.S. Over the course of the remainder of 2021, PYLARIFY availability expanded into additional regions and is now broadly available nationwide. The Company continues to expand its geographic coverage, customer contracting and market access coverage to serve its customers and the U.S. prostate cancer community.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial launch of PYLARIFY is complex and expensive. During 2021, the Company hired additional employees to assist it with the commercialization of PYLARIFY, including in sales, marketing, reimbursement, quality and medical affairs. To manufacture PYLARIFY, the Company assembled and qualified a nationwide network of PMFs with radioisotope-producing cyclotrons that make F 18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. After being made on a cyclotron at a PMF, the F 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY. The finished PYLARIFY is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses of the final product. Because each of the PMFs manufacturing these products is deemed by the FDA to be a separate manufacturing site, each has to be approved by the FDA. Although PYLARIFY is now broadly available nationwide, the Company can give no assurance that the FDA will continue to approve PMFs in accordance with the Company’s planned roll-out schedule. If FDA approval of manufacturing sites is delayed or withdrawn, the Company’s future business, results of operations, financial condition and cash flows could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commercial launch also required the Company to obtain adequate coding and coverage for PYLARIFY, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels, which adequately cover our customers’ costs of using PYLARIFY in PET/CT imaging procedures. We received notification that our HCPCS code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, CMS granted Transitional Pass-Through Payment Status in the hospital outpatient setting (“TPT Status”) for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in this setting. TPT Status for PYLARIFY is expected to expire December 31, 2024. After TPT Status expires, under current Medicare rules, PYLARIFY, similar to other diagnostic radiopharmaceuticals, would not be separately reimbursed in the hospital outpatient setting but rather would be included as part of the facility fee a hospital otherwise receives for a PET/CT imaging procedure, and the facility fee does not always cover the cost of a drug used in the procedure. The Company can give no assurance that any CMS reimbursement in the hospital outpatient setting that follows the expiration of TPT Status will be adequate to cover the cost of PYLARIFY used in a PET/CT imaging procedure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020 and through the date of this filing, including the impact of hospital staffing challenges, vaccination mandates, employee absences due to illness, and a decline in the volume of certain procedures and treatments using the Company’s products. For example, we believe that during the fourth quarter of 2021 sales of DEFINITY were impacted by hospital nursing and sonographer shortages, and sales of AZEDRA were impacted by treatment capacity constraints in hospitals, treatment deferrals and cancellations by patients, and access restrictions by hospitals. There has also been a substantial reduction in pulmonary ventilation studies in which the Company’s product, Xenon, is used. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives. For most of the second quarter of 2020, the Company reduced the Company’s work week from five days to four days and reduced the pay for employees by varying amounts depending on level of seniority.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives and paused new enrollment in the ARROW Phase 2 study of 1095, a PSMA-targeted therapeutic, in metastatic castrate-resistant prostate cancer (“mCRPC”) patients to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020. GE Healthcare Limited (“GE Healthcare”), the Company’s development and commercialization partner for flurpiridaz fluorine-18 F 18, also delayed enrollment in the second Phase 3 clinical trial of flurpiridaz F 18 because of the pandemic and resumed enrollment in the third quarter of 2020.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although some of the restrictions, including stay-at-home mandates, imposed in response to the COVID-19 pandemic have been lifted in much of the United States (the “U.S.”), and there has been a rapid rollout and development of multiple vaccines and boosters, the resurgence of COVID-19 infections continued to impact certain aspects of the Company’s business during 2021 and the pandemic could still have a future negative impact on the Company's business, particularly if there are additional resurgences as a result of mutations or other variations to the virus that increase its communicability or its impact on certain populations, geographic regions and the healthcare system, including elective procedures and hospital access.</span></div>
CY2020Q1	lnth	Business Combination Consideration Transferred Equity Interests Issued And Issuable Shares BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares	26844877	shares
CY2020Q1	lnth	Business Combination Consideration Transferred Contingent Value Right BusinessCombinationConsiderationTransferredContingentValueRight	86630633	shares
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks and Limited Suppliers</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to clinics, distributors, group practices, hospitals, integrated delivery networks and radiopharmacies.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2022, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through March 31, 2022, and for which the Company is currently negotiating an extension. The Company also has a Xenon supply agreement with IRE which runs through December 31, 2023, with auto-renewal provisions and terminable upon notice of non-renewal. The Company currently relies on IRE as the sole supplier of bulk-unprocessed Xenon which the Company processes and finishes for its customers. The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, Cardiolite and evacuation vials for TechneLite.</span></div>
CY2021Q4	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	6100000	USD
CY2020Q4	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	0	USD
CY2021	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustments Related To Previous Period BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod	2600000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	17500000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	5200000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	3800000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-274000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-260000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	33000	USD
CY2021	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-7121000	USD
CY2020	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	2218000	USD
CY2019	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-10635000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	45000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	238000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	686000	USD
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2020	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	3453000	USD
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2000	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	242000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7350000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2198000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6221000	USD
CY2021Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	700000	USD
CY2020Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	600000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	425208000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	339410000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	347337000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	425208000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	339410000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	347337000	USD
CY2020	lnth	Rebates And Allowances Reclassified RebatesAndAllowancesReclassified	19100000	USD
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	25772000	USD
CY2021	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	14000	USD
CY2019	lnth	Rebates And Allowances Reclassified RebatesAndAllowancesReclassified	16600000	USD
CY2021	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	standard payment terms are 30 to 60 days
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	24159000	USD
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	10977000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	6985000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	19675000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-604000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	16706000	USD
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	9350000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	9300000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	49797000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	86200000	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	86200000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	11300000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	46757000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15800000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	17708000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	11300000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	9300000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	15800000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	0	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	10100000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	16600000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	2000000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1200000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-70400000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	800000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	11300000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	86200000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	15800000	USD
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-72400000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-76389000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5495000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	25432000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1351000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5984000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3195000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75038000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11479000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28627000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	287000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-8166000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3158000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4437000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1334000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8712000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-13166000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-30000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	170000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	114000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-8196000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3328000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12765000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1048000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1506000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3058000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-178000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	790000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	331000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	350000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	223000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9725000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3759000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1994000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3040000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15758000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2411000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	6012000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1764000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1176000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3210000	USD
CY2021	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts	0	USD
CY2020	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts	2723000	USD
CY2019	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionCosts	0	USD
CY2021	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale	0	USD
CY2020	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale	-3000000	USD
CY2019	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Recognition Of Deferred Tax Asset Held For Sale EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRecognitionOfDeferredTaxAssetHeldForSale	0	USD
CY2021	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162 EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162	1028000	USD
CY2020	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162 EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162	717000	USD
CY2019	lnth	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162 EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162	527000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170562000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-8952000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2818000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-13156000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	990000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	1065000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	1685000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	656000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1457000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1914000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3049000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	15015000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	230000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	23000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-254000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	635000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3759000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-238000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-400000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-318000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-22000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1164000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-128000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2768000	USD
CY2021	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	-1786000	USD
CY2020	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	590000	USD
CY2019	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	-2531000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	184000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	639000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1994000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3040000	USD
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	4292000	USD
CY2020Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	5867000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	27159000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	32030000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	297000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	404000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	768000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2553000	USD
CY2021Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	502000	USD
CY2020Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	1325000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	122944000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	127369000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1102000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1014000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	157064000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	3026000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	5676000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	87351000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	91283000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	90377000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	96959000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3923000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3456000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	62764000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	70147000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	62764000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	70147000	USD
CY2020Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	92300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5300000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	16500000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5292000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5292000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	188000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1446000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3658000	USD
CY2021Q4	lnth	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	20900000	USD
CY2020Q4	lnth	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	29900000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	23500000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	1000000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-9000000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2800000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-13200000	USD
CY2021Q4	lnth	Tax Indemnification Agreement Receivable TaxIndemnificationAgreementReceivable	13500000	USD
CY2020Q4	lnth	Tax Indemnification Agreement Receivable TaxIndemnificationAgreementReceivable	20800000	USD
CY2021	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-7100000	USD
CY2020	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	2200000	USD
CY2019	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-10600000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	15505000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16000000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13042000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11212000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6582000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8532000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	35129000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	35744000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	205687000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	196583000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88915000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	76412000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116772000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120171000	USD
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	13200000	USD
CY2020	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	12500000	USD
CY2019	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	10300000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7300000	USD
CY2020Q4	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1800000	USD
CY2020Q4	lnth	Payment For Contract Termination PaymentForContractTermination	500000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	350315000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	382323000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-29190000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-42032000	USD
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	26400000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	15640000	USD
CY2020Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	14020000	USD
CY2021	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	5259000	USD
CY2021	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1554000	USD
CY2021Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	20833000	USD
CY2021	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	5300000	USD
CY2021Q4	lnth	Financial Assurance In Form Of Surety Bond FinancialAssuranceInFormOfSuretyBond	28200000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	15640000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	489960000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	141450000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	348510000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	148440000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	148440000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	489945000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	113933000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	376012000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27500000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10800000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	18300000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	2700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	33229000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	32634000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	32563000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	32508000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	32497000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	169439000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	332870000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	58632000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	15714000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2557000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	42918000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	61189000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	58632000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22730000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17669000	USD
CY2021Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	16157000	USD
CY2020Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	5653000	USD
CY2021Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	10977000	USD
CY2020Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	9350000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2850000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2925000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5354000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6129000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	58068000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	41726000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16546000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17501000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	86200000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	15800000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	22148000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	30092000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124894000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	63393000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	11250000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	15000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	148750000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	175000000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	498000	USD
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	430000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	691000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	174763000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11642000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	163121000	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3200000	USD
CY2020Q4	lnth	Capitalized Debt Issuance Cost CapitalizedDebtIssuanceCost	2800000	USD
CY2019	lnth	Debt Instrument Covenant Compliance Number Of Financial Covenants DebtInstrumentCovenantComplianceNumberOfFinancialCovenants	2	financial_covenant
CY2019Q4	lnth	Debt Instrument Covenant Compliance Minimum Interest Coverage Ratio DebtInstrumentCovenantComplianceMinimumInterestCoverageRatio	3.00
CY2019	lnth	Debt Instrument Covenant Leverage Ratio Increase Election Amount Numberof Separate Times DebtInstrumentCovenantLeverageRatioIncreaseElectionAmountNumberofSeparateTimes	2	time
CY2021Q4	us-gaap	Interest Rate Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months Net InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet	-300000	USD
CY2021Q4	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	100000	USD
CY2020Q4	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	500000	USD
CY2021	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	838000	USD
CY2021	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-725000	USD
CY2020	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-1503000	USD
CY2020	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-415000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9180277	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15934000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	860461	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.12
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14075000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12492000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1575219	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.03
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	318662	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.62
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	283618	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	22.74
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	972939	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.73
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10145135000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y3M18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8672206000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	318662	shares
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8868	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	67558	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	600000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1107866	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	16.58
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1000259	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.14
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	524117	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	16.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	253634	shares
CY2021Q4	lnth	Lease Right Of Use Asset LeaseRightOfUseAsset	9344000	USD
CY2020Q4	lnth	Lease Right Of Use Asset LeaseRightOfUseAsset	18966000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	17.40
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1330374	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	19.04
CY2021Q4	lnth	Number Of Operating Leases NumberOfOperatingLeases	2	lease
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8788000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18441000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	556000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	525000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1599000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	21000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1164000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	392000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	249000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16546000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17501000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	299000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	246000	USD
CY2021Q4	lnth	Lease Liability LeaseLiability	18836000	USD
CY2020Q4	lnth	Lease Liability LeaseLiability	19160000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P9Y
CY2021	us-gaap	Impairment Lessor Asset Under Operating Lease ImpairmentLessorAssetUnderOperatingLease	9500000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2312000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1471000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	330000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	196000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	28000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	70000	USD
CY2021	us-gaap	Lease Cost LeaseCost	2678000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1758000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.046
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2071000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1202000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	28000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	21000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	339000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2450000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	207000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	683000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19210000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	556000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	373000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2359000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	406000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2404000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	268000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	30893000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	105000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2497000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2491000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9786000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21987000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	779000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3842000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	88000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18145000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	691000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38758000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10113000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9175000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Asset Current BusinessCombinationContingentConsiderationAssetCurrent	2500000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Asset Current BusinessCombinationContingentConsiderationAssetCurrent	0	USD
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	205000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	450000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12818000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9625000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8788000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18441000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Asset Noncurrent BusinessCombinationContingentConsiderationAssetNoncurrent	6800000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Asset Noncurrent BusinessCombinationContingentConsiderationAssetNoncurrent	11300000	USD
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	23170000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60634000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-71279000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-13473000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67486000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54134000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38988000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	75000	shares
CY2021	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	0	shares
CY2020	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	0	shares
CY2019	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	1050000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67486000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54134000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40113000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2893000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3175000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50000	shares
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	3483000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	3000000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	6483000	USD
CY2021Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	300000	USD
CY2021Q4	lnth	Contingent Payments Under Companys License Agreements ContingentPaymentsUnderCompanysLicenseAgreements	170500000	USD
CY2021	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	24000000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2600000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment

Files In Submission

Name	View Source	Status
0001628280-22-003657-index-headers.html	Edgar Link	pending
0001628280-22-003657-index.html	Edgar Link	pending
0001628280-22-003657.txt	Edgar Link	pending
0001628280-22-003657-xbrl.zip	Edgar Link	pending
ex211subsidiariesq42021.htm	Edgar Link	pending
ex231consentq42021.htm	Edgar Link	pending
ex311ceocertificationq42021.htm	Edgar Link	pending
ex42descriptionofregistran.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lnth-20211231.htm	Edgar Link	pending
lnth-20211231.xsd	Edgar Link	pending
lnth-20211231_cal.xml	Edgar Link	unprocessable
lnth-20211231_def.xml	Edgar Link	unprocessable
lnth-20211231_g1.jpg	Edgar Link	pending
lnth-20211231_htm.xml	Edgar Link	completed
lnth-20211231_lab.xml	Edgar Link	unprocessable
lnth-20211231_pre.xml	Edgar Link	unprocessable
lnth10k-123121ex312.htm	Edgar Link	pending
lnth10k-123121ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNTH
Lantheus Holdings, Inc. Stock $lnth

2021 Q4 Form 10-K Financial Statement

#000162828022003657 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH Lantheus Holdings, Inc. Stock $lnth

2021 Q4 Form 10-K Financial Statement

#000162828022003657 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH
Lantheus Holdings, Inc. Stock $lnth